18kDa转位蛋白TSPO:应激相关障碍的新诊断或治疗靶点
应激相关障碍如抑郁症的治疗仍面临起效慢、苯二氮䓬类长期使用受限等挑战。TSPO作为主要位于线粒体的跨膜蛋白,介导类固醇生成和线粒体生物能量学,其配体已用于PET显像作为应激相关障碍中小胶质细胞活化和神经炎症的推测性标志物,并在动物和人类中显示出调节神经可塑性及抗抑郁抗焦虑疗效。TSPO可能为理解应激相关障碍病理生理和开发新治疗选择开辟新途径。
要点
- TSPO配体在PET研究中用作应激相关障碍小胶质细胞活化和神经炎症的推测性标志物。
- TSPO配体在动物和人类中调节神经可塑性并产生抗抑郁和抗焦虑疗效。
- 促进内源性神经类固醇生成是外源性神经类固醇给药的有吸引力的替代方案。
核心结论
- TSPO可能为理解应激相关障碍的病理生理和开发新治疗选择开辟新途径。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 苯二氮䓬类是GABAA受体的正向变构调节剂,其长期使用受耐受性发展、滥用倾向和认知损害限制。
- 3α-还原神经类固醇如别孕烯醇酮也是GABAA受体正向变构调节剂,但作用位点不同于苯二氮䓬类。
- 给予brexanolone或zuranolone等神经类固醇已显示可快速改善产后抑郁或重性抑郁障碍症状。
- TSPO是主要位于线粒体的跨膜蛋白,介导类固醇生成和线粒体生物能量学等多种生物学功能。
- TSPO配体在PET研究中用作应激相关障碍小胶质细胞活化和神经炎症的推测性标志物,并在动物和人类中调节神经可塑性、产生抗抑郁和抗焦虑疗效。
关键数值与推荐
- 原文未报告具体诊断标准、阈值或推荐等级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Efficient treatment of stress-related disorders, such as depression, is still a major challenge. The onset of antidepressant drug action is generally quite slow, while the anxiolytic action of benzodiazepines is considerably faster. However, their long-term use is impaired by tolerance development, abuse liability and cognitive impairment. Benzodiazepines act as positive allosteric modulators of ɣ-aminobutyric acid type A (GABAA) receptors. 3α-reduced neurosteroids such as allopregnanolone also are positive allosteric GABAA receptor modulators, however, through a site different from that targeted by benzodiazepines. Recently, the administration of neurosteroids such as brexanolone or zuranolone has been shown to rapidly ameliorate symptoms in post-partum depression or major depressive disorder. An attractive alternative to the administration of exogenous neurosteroids is promoting endogenous neurosteroidogenesis via the translocator protein 18k Da (TSPO). TSPO is a transmembrane protein located primarily in mitochondria, which mediates numerous biological functions, e.g., steroidogenesis and mitochondrial bioenergetics. TSPO ligands have been used in positron emission tomography (PET) studies as putative markers of microglia activation and neuroinflammation in stress-related disorders. Moreover, TSPO ligands have been shown to modulate neuroplasticity and to elicit antidepressant and anxiolytic therapeutic effects in animals and humans. As such, TSPO may open new avenues for understanding the pathophysiology of stress-related disorders and for the development of novel treatment options.
引用
- Rupprecht R, Wetzel CH, Dorostkar M, et al. Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders? Mol Psychiatry. 2022. PMID: 35444254. doi:10.1038/s41380-022-01561-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。